



IPO : Bio Medica Laboratories Limited

May 2026

Snapshot

Bio Medica Laboratories Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare and medicinal products. The company focuses on quality-driven production practices and operates manufacturing facilities designed to meet industry standards and regulatory requirements. Its product portfolio caters to multiple therapeutic segments, supporting healthcare demand across domestic markets. With experienced promoters and an emphasis on operational efficiency, the company aims to strengthen its market presence through capacity expansion, technology adoption, and customer-focused services. Bio Medica Laboratories continues to position itself as a growing participant in India's expanding pharmaceutical and healthcare industry.

Company Vision

Bio Medica Laboratories Limited envisions becoming a trusted and innovative healthcare company by delivering high-quality pharmaceutical products that improve patient well-being and support the growing healthcare needs of society. The company aims to strengthen its presence across domestic and international markets through continuous product development, advanced manufacturing practices, and strict quality standards. It focuses on building long-term relationships with customers, healthcare professionals, and business partners while maintaining ethical business practices. By investing in technology, operational efficiency, and skilled human resources, the company seeks sustainable growth and aims to establish itself as a reliable name in the pharmaceutical industry.

Growth Prospects

Bio Medica Laboratories Limited has promising growth prospects driven by the rising demand for affordable healthcare products and the continuous expansion of the pharmaceutical industry in India. Its focus on quality manufacturing, product diversification, and operational efficiency may support revenue growth and market expansion. Investments in advanced technology, capacity enhancement, and regulatory compliance can further strengthen competitiveness. Additionally, supportive government policies for the pharmaceutical sector and increasing demand for generic medicines provide favorable long-term opportunities for sustainable business growth and improved profitability.

Opening Date	Thursday, May 21, 2026
Closing Date	Monday, May 25, 2026
Price Band	Rs. 132 to Rs. 139 per share
Bid Lot	1000 Shares
Face Value	Rs. 10 per share
Issue Size	37,72,000 shares (aggregating up to Rs. 52 Cr)
Reserved for Market Maker	1,89,000 shares (aggregating up to Rs. 3 Cr)
Fresh Issue	32,06,000 shares (aggregating up to Rs. 45 Cr)
Registrar	Skyline Financial Services Pvt.Ltd.

Key Financials

Amount in cr.	Nov-2025	FY2025	FY2024	FY2023
Assets	65.17	39.12	19.53	17.57
Total Income	28.63	38.33	15.34	16.25
Profit After Tax	8.66	9.79	2.50	0.33
EBITDA	13.45	15.21	5.63	1.70
NET Worth	17.12	14.73	4.94	2.44
Reserves and Surplus	7.94	5.55	4.84	2.34
Total Borrowing	38.17	15.01	10.49	9.61

Risk Assessment

Q-Line Biotech Limited faces several business risks that could impact its future performance and profitability. The company operates in a highly competitive pharmaceutical and biotechnology industry where pricing pressure, changing customer preferences, and competition from larger established players may affect growth. Regulatory compliance requirements and changes in healthcare policies can also increase operational challenges and costs. Dependence on suppliers, distribution networks, and working capital availability may influence business continuity. Additionally, fluctuations in raw material prices and economic uncertainties could impact margins. Any failure to maintain product quality standards or expand market presence may adversely affect the company's reputation and financial stability.